Anesta
United States Updated 9 July 2026
Anesta is a finished-dose manufacturer based in United States. It appears in 2 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by ANVISA (Brazil) and US FDA. Its most recent recorded inspection, by US FDA, closed on 30 August 2024 as VAI.
2
registered plants
1 with an FDA FEI number
2
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 30 August 2024 VAI US FDA
- 10 December 2019 NAI US FDA
- 24 May 2019 NAI US FDA
- 3 March 2017 VAI US FDA
- 16 January 2015 VAI US FDA
- 3 August 2012 NAI US FDA
- 22 October 2010 VAI US FDA
- 19 June 2009 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| SALT LAKE CITY, United States | Not on file |
| Salt Lake City, United States | 1000149927 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| ARCSA (EC) | 2 | None |
| ANVISA (Brazil) | None | 3 |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Anesta comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 30 August 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates